Takeda announces Ninlaro US availability

CAMBRIDGE, Mass. — Takeda Pharmaceuticals recently announced the U.S. availability of its Ninlaro (ixazomib), an oral proteasome inhibitor. Ninlaro is indicated to treat patients with multiple myeloma who have received at least one prior therapy.  The Food and Drug Administration approved the drug four months ahead of the date of its Priority Review. 

 

“In addition to the clinical investigators and patients, I would like to extend our thanks to the FDA for its expedited review of Ninlaro.” Takeda Oncology president Dr. Christophe Bianchi said. “We are excited to realize our commitment to the multiple myeloma community as we bring Ninlaro to patients.”

 

Ninlaro, because it is a pill that can be taken at home, could be logistically easier for patients, the company said. Takeda is offering its Ninlaro 1Point support program through Ninlaro.com to help patients with access and coverage questions. 

 

“Access to therapy for patients in need is our first and foremost priority,” Ryan Cohlhepp, Takeda’s VP U.S. marketing, said. “And with NINLARO 1Point, we have created a robust suite of support services to help patients access NINLARO.”